Southern California Psychiatry: Overview of New Brokers in Schizophrenia and Dementia

Towards a Muscarinic Agent Answer for the Presynaptic Dopamine Downside in Schizophrenia

Analysis on Cobenfy (xanomeline-trospium) presents a novel method to administration of schizophrenia by concentrating on muscarinic acetylcholine receptors. By avoiding dopamine receptor blocking, this drug reduces danger of tardive dyskinesia and different adversarial motor results. Gus Alva, MD, Jonathan Meyer, and Chelsie Monroe, APN, introduced findings on this new medicine. Learn in regards to the presentation right here.

Remedy-Resistant Despair and Effectively-Rounded Care, With Alejandro Alva at Southern California Psychiatry

Alejandro Alva, MD, mentioned the varied methods to deal with melancholy and contemplating all out there remedy modalities. Remedies like transcranial magnetic stimulation, vagal nerve stimulation, ketamine, and esketamine, could be selections for sufferers with remedy resistant melancholy. Alva identified that clinicians must also be sure you handle psychosocial elements of melancholy to make sure well-rounded care. Watch the total video interview right here.

Addressing Agitation in Dementia: Rising Choices and Medical Issues

Discussing agitation in dementia, Gerald Maguire, MD, famous that the panorama is starting to shift. With Rexulti (brexpiprazole) approval for agitation in dementia, new pharmacological choices can be found to those sufferers. Nevertheless, he famous, immediate intervention and addressing life-style components can also be important. View the total interview right here.

Clinician Suggestions in Prescribing New Xanomeline-Trospium for Schizophrenia

Returning to dialogue of Cobenfy, Chelsie Monroe, MSN, APN, PMHNP-BC, expressed enthusiasm for this remedy’s potential in remedy resistant schizophrenia. When transitioning sufferers who could already be taking clozapine, clinicians needs to be cautious about destabilization and contemplate totally whether or not this muscarinic agent is an efficient match. This new remedy possibility represents a brand new mechanism of motion, Monroe identified, avoiding lots of the adversarial results usually seen in conventional antipsychotics. See the total video interview right here.